- 1 Behavior-change interventions to improve antimicrobial stewardship in human health, animal health, and
- 2 livestock agriculture: A systematic review
- 3 Jessica Craig<sup>1\*</sup>, Rachel Sadoff<sup>2</sup>, Sarah Bennett<sup>3</sup>, Felix Bahati<sup>4,5</sup>, Wendy Beauvais<sup>1</sup>
- <sup>4</sup> <sup>1</sup>Purdue University, College of Veterinary Medicine, Department of Comparative Pathobiology, Indiana,
- 5 47906 USA
- 6 <sup>2</sup>Columbia University, Mailman School of Public Health, New York, USA
- 7 <sup>3</sup>King's College London, London, UK
- 8 <sup>4</sup>KEMRI Wellcome Trust Research Programme, Health Services Research Unit, Nairobi, Kenya
- 9 <sup>5</sup>Jomo Kenyatta University of Agriculture and Technology, College of Health Sciences, Department of
- 10 Environmental Health and Disease Control, Nairobi, Kenya
- 11 \*Corresponding author <u>craig119@purdue.edu</u>

# 12 Abstract

13 Antimicrobial resistance (AMR) is an economic, food security, and global health threat that is driven by a multitude of factors including the overuse and misuse of antimicrobials in the human health, 14 animal health, and agriculture sectors. Given the rapid emergence and spread of AMR and the relative 15 16 lack of development of new antimicrobials or alternative therapies, there is a need to develop and 17 implement non-pharmaceutical AMR mitigation policies and interventions that improve antimicrobial 18 stewardship (AMS) practices across all sectors where antimicrobials are used. We conducted a systematic literature review per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines 19 20 to identify peer-reviewed studies that described behavior-change interventions that aimed to improve 21 AMS and/or reduce inappropriate antimicrobial use in the human health, animal health, and livestock agriculture stakeholders. We identified 301 total publications -11 in the animal health sector and 290 in 22 23 the human health sector – and assessed these interventions using metrics across five thematic areas- (1) 24 antimicrobial use (AMU), (2) adherence to clinical guidelines, (3) AMS, (4) AMR, and (5) clinical outcomes. The lack of studies in the animal health sector precluded a meta-analysis. Among studies in the 25 26 human health sector, 35.7% reported significant (p<0.05) pre- to post-intervention decreases in AMU. 27 73.7% reported significant improvements in adherence of antimicrobial therapies to clinical guidelines, 28 45% demonstrated significant improvements in AMS practices, 45.5% reported significant decreases in 29 the proportion of isolates that were resistant to antibiotics or the proportion of patients with drug-resistant infections across 17 antimicrobial-organism combinations, and few studies reported statistically 30 31 significant changes in clinical outcomes. We did not identify any overarching intervention type nor 32 characteristics associated with successful improvement in AMS, AMR, AMU, adherence, nor clinical 33 outcomes.

# 34 Introduction

35 Antimicrobial resistance (AMR) is an economic, food security, and global health threat (1-3). 36 Globally, there were an estimated 4.95 million and 1.27 million human deaths associated with or directly attributable to drug-resistant bacterial infections, respectively, in 2019 (4). The Centers for Disease 37 38 Control and Prevention estimates that the annual cost to treat hospital- and community-acquired drug-39 resistant bacterial infections in the US alone is \$4.6 billion due to prolonged hospital stavs, more complex 40 healthcare needs, and treatment with second- and third-line antimicrobial therapies (5). In addition to the human health burden. AMR among pathogens affecting animals has adverse animal welfare impacts and 41 42 imposes additional treatment costs on animal owners, ultimately leading to increased costs of food 43 production. The emergence of new drug-resistant pathogens may also hinder global food and animal trade (3.6). Researchers estimate that AMR may cause a 7.5 percent decline in global livestock production by 44 45 2050 (7).

Drug resistance is driven by a multitude of factors including the overuse and misuse of 46 antimicrobials in the human health, animal health, and agriculture sectors. Although antimicrobial use 47 (AMU) and consumption (AMC) surveillance is limited in the human and animal health sectors, available 48 evidence demonstrates that AMU is increasing globally. Analysis of AMC rates, approximated from data 49 50 on national-level antimicrobial sales data, indicated a 39% increase in per capita AMC in the human 51 health sector between 2000 and 2015, rising from 11.3 to 15.7 daily defined doses per 1,000 people per day (DIDs) (8). Concerningly, the use of World Health Organization-designated "Watch" antibiotics has 52 53 increased faster than "Access" antibiotics. Between 2000 and 2015, there was a 90.9% increase in the global per capita consumption of "Watch" antibiotics, from 3.3 to 6.3, compared to a 26.2% increase in 54 55 the global per capita consumption "Access" antibiotics which rose from 8.4 to 10.6 DIDs in the same period (9). Previous studies show clinically inappropriate AMU rates as high as 55% in South Africa, 56 88% in Pakistan, and 61% in China in the human health sector; however, emerging evidence suggests 57 there is significant heterogeneity in AMU practices across countries and clinical settings (10–13). Best 58

available evidence suggests that AMU in the animal health sector is rising as the global demand for
animal products increases (14). In 2017, there were an estimated 93,309 tons (95% confidence interval
[CI]: 64,443-149,886) of antimicrobials sold for use in chicken, cattle, and pig systems across 41
countries. In the same year, AMC in the aquaculture sector was estimated at 10,259 tons across six fish
species in 33 countries (15). By 2030, AMU is projected to rise to 104,079 tons among chicken, cattle,
and pigs and to 13,600 tons among fish (14,15).

Concerningly, the emergence and evolution of drug-resistant microorganisms is outpacing the 65 development of new antimicrobial agents. In the past 50 years, no new antimicrobial agents active against 66 67 gram-negative bacteria have been brought to market, and only 5 of the 20 major global pharmaceutical companies are engaged in antimicrobial research and development (R&D) (16). Investment in 68 antimicrobial R&D is not considered lucrative given the challenges in antimicrobial discovery, rapid 69 70 introduction of generic formulations, and the speed at which microorganisms develop resistance to 71 antimicrobials. Moreover, new antimicrobials are likely to be reserved for special or emergency use to preserve their efficacy; therefore, there would paradoxically be less demand for these drugs. 72 73 While AMR poses an increasing public health threat, the number of deaths that could have been 74 prevented by improving access to antimicrobials, about 5.7 million in low- and middle-income countries 75 (LMICs), exceeds the morbidity and mortality burden from AMR indicating that access to clinically

appropriate antimicrobials for the treatment of infectious diseases remains a critical issue (16).

77 Given the health and economic impacts of AMR, challenges around access to appropriate 78 antimicrobial therapies, and the lack of antimicrobial R&D, there is an urgent need to develop and 79 implement impactful non-pharmaceutical AMR mitigation policies and interventions that improve antimicrobial stewardship (AMS) practices in the human health, animal health, and agriculture sectors. 80 81 There is a growing body of literature describing such non-pharmaceutical AMS interventions which 82 include education, training, and health information campaigns to improve awareness and knowledge 83 among technical stakeholders and the public; installing AMS committees in healthcare facilities to approve and/or review prescription practices; and developing and implementing standard clinical 84

85 treatment guidelines or clinical treatment algorithms which provide clinicians with an evidence-based resource to guide clinical decision making around AMU and prescription (17–19). Despite this emerging 86 87 evidence, there remains no consensus on what constitutes the most impactful or cost-effective AMS practices across various sectors and settings. Therefore, the purpose of this study was to conduct a 88 89 systematic literature review and meta-analysis to identify behavior-change interventions aimed at improving AMS and AMU across the human health, animal health, and agriculture sectors to identify 90 91 gaps in the evidence base or to describe trends towards best AMS practices in various resource and 92 income settings.

# 93 Materials and Methods

94 This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (20). We searched PubMed, Web of Science, Embase, 95 96 Centre for Agriculture and Bioscience International (CABI), and the Cochrane Database of Systematic 97 Reviews for peer-reviewed studies that described behavior-change interventions that aimed to improve AMS and/or reduce inappropriate AMU or AMC among human health, animal health, and livestock 98 agriculture stakeholders including but not limited to health providers, patients, farmers, or animal owners 99 100 (21–25). Two searches were conducted; the first on 15 June 2021 identified studies published prior to 15 101 June 2021 and a second search conducted on 31 August 2022 identified studies published between 15 June 2021 and 31 August 2022 (inclusive). The following search string was used to search the title and 102 103 abstracts of published entries within each database: (intervention OR trial) AND (antimicrobial" OR 104 antibiotic) AND (use OR stewardship OR consumption OR prescription). Two researchers independently screened returned entries for eligibility in a two-step process: a 105 106 review of the title and abstract followed by full-text review, according to the following criteria: (1) Only 107 scientific articles published in peer-reviewed journals were included; pre-prints, course completion papers 108 or theses, and internal reports or policy briefs were excluded. (2) Papers published in any language and written on interventions conducted in any country were included. (3) All study types including 109

110 randomized controlled trials and observational studies (including pre/post study designs) were 111 included. Review articles were screened for additional relevant studies. (4) Studies were included if they 112 reported on at least one outcome which fell into three general categories: (a) AMU or AMC; (b) adherence/compliance of antimicrobial therapy to facility, national, or international clinical treatment 113 114 guidelines; and (c) rates of specific stewardship practices such as the intravenous to oral therapy 115 conversion rates, frequency of obtaining specimen cultures for pathogen identification and/or 116 antimicrobial susceptibility tests. For studies that reported on at least one primary outcome, we also 117 extracted data for this study's secondary outcomes which included the incidence or prevalence of drug-118 resistant infections; length of stay in the healthcare facility or specific unit (such as intensive care); health 119 outcomes such as patient/animal mortality or rehospitalization rates; and the economic or cost impact of interventions. (5) Non-relevant papers that did not describe interventions aimed at changing behaviors to 120 121 optimize AMU, AMC, or AMS in the human health, animal health, or livestock agriculture sectors or 122 those that did not report on our primary outcomes of interest were excluded. Therefore, studies such as those that reported solely on changes in knowledge, attitudes, and perceptions regarding AMR or AMU 123 124 were excluded as were studies that assessed drug or drug regimen efficacy. (6) Studies were also excluded 125 if the full text was unavailable or unobtainable, if results and statistics were not presented numerically 126 (such as only presented graphically), or if insufficient data was reported to conduct statistical analyses 127 such as to calculate odds ratios or risk ratios or conduct t-tests or Chi-square tests. At each stage, two reviewers independently screened entries for eligibility, identified discrepancies, and re-evaluated articles 128 until a consensus was reached. Duplicates were identified when results from each search were combined 129 130 into a single database.

Data extraction was conducted by one researcher (JC, SB, FB) and reviewed by a second (JC, SB, and FB); data was compiled using Microsoft Excel software. We used a standardized spreadsheet (S4 file) to extract data from each publication that met our inclusion criteria, including the publication year, country and setting on the intervention, type of evaluation, type of study, description of intervention, intervention start and end date and duration, total sample size and unit of sample size, the study's

outcome, and all relevant numerical data reported. The income classification of the country where the
intervention occurred, per the World Bank's 2021 classification, was also extracted (26). We classified
studies as being either single or multi-center and we classified interventions either single or bundled
(meaning more than one type of intervention occurred), based on the publication. Duration of intervention
was computed, if not provided in the study, using the intervention start and end dates.

For the meta-analysis, we created syntheses based on three criteria: type of statistic reported, 141 study type, and outcome variables. First, studies were categorized by type of statistic (rates or 142 143 proportions) reported. Then studies were categorized by study type or data analysis/reporting 144 methodology. These categories included: pre/post observational studies; randomized or non-randomized control trials (RCTs) that compared a control arm to an experimental/intervention arm; randomized or 145 non-randomized control trials that compared one intervention arm to another intervention arm; and time 146 147 series studies. We then categorized the studies by outcome. For all studies, odds ratio, rate ratio, 95% confidence interval, chi-square statistic, Wilcoxon signed-rank test, and independent or dependent t-test 148 statistics were calculated, as relevant, to compare the study arms or pre- to post-intervention changes 149 150 according to the study outcomes. Bivariate analyses and linear and logistic regression analyses were 151 conducted across studies to identify trends in intervention success in various settings. For logistic 152 regression analyses for the pre- to post-intervention studies, a categorical variable was created with 3 153 categories indicating if there was a significant increase, significant decrease, or no statistically significant change in pre- to post-intervention outcomes. Backwards stepwise elimination process based on 154 155 likelihood ratio tests was used to build final regression models. The Quality Assessment Tool for 156 Quantitative Studies was used to assess study quality and risk of bias (27). For the quality assessment, each study was independently reviewed by two researchers with a third to resolve disputes and compute a 157 158 consensus quality score.

# 159 **Results**

160	Our review returned a total of 154,106 publications of which 4,893 were duplicates; 148,639
161	were determined to be irrelevant based on the title and abstract review; and 36 were identified as review
162	articles. Following full-text review, a total of 301 publications – 11 in the animal health sector and 290 in
163	the human health sector (S1 and S2 files) – met the study's inclusion criteria and underwent data
164	extraction (Fig 1). Per the Quality Assessment Tool for Quantitative Studies, 4 of 11 studies that
165	described interventions in the animal health or agriculture sectors (36.4%) were determined to have strong
166	overall quality ratings, 3 (27.3%) had moderate quality ratings, and 4 (36.4%) had weak quality ratings
167	while 129 of the 290 studies (44.5%) that described interventions in the human health sector were
168	determined to have strong overall quality, 115 (39.7%) had moderate overall quality, and 46 (15.9%) had
169	low overall quality scores (S3 file). A common reason for low quality scores was a high risk of selection
170	bias or failing to control for potential cofounders.

Fig 1. Flow diagram of systematic literature review describing behavior change interventions to
improve antimicrobial use and stewardship in the animal and human health sectors.

# 173 Animal health and agriculture sectors

174 Only 11 studies conducted in the animal health or agriculture sector met our study's inclusion 175 criteria, and given heterogeneity across the study types, outcomes, and types of statistics reported, a meta-176 analysis was not possible. Seven of the studies (63.6%) assessed the impact of interventions among foodproducing animals including swine (n=3), poultry (n=1), dairy cows (n=2), and calves (n=1) (28–34). 177 178 Four studies (36.4%) assessed interventions in companion animals (35–38). Year of study publication 179 ranged from 2014 to 2021. Across the 11 studies, 8 countries were represented (Germany, Sweden, 180 Netherlands, Belgium, France, Switzerland, the United Kingdom, and Vietnam). Interventions ranged 181 from 5 months in duration to 5 years. Five studies (45.5%) implemented bundled interventions while the 182 remaining 7 studies (63.6%) tested single interventions. Four studies (36.4%) implemented online AMS 183 tools that either provided guidance on AMU and AMS or restricted antimicrobial prescriptions. Other 184 interventions included veterinary guidance on husbandry, biosecurity, or AMU; educational programs;

185 review and feedback of AMU; and programs to implement infection prevention and control measures. 186 Overall AMU decreased significantly (p value < 0.05) for all but one study which implemented an online 187 stewardship tool among calf farmers in Switzerland (29). Three studies assessed pre- to post-intervention changes in animal health status and productivity and documented either no change or an improvement in 188 189 mortality, animal weight gain, or feed conversion ratio associated with the intervention (28,32,33). One study that implemented a voluntary AMS program among pig farmers in France documented a 90% 190 191 reduction in cephalosporin usage between 2010 and 2016 and demonstrated a reduction in drug-resistance 192 among commensal and pathogenic *Escherichia coli* isolates sampled during the same period (31).

## 193 Human health sector

194 Of the 290 studies that assessed behavior-change interventions in the human health sector, 40

195 (13.7%) were RCTs, 237 (81.7%) were pre/post observational studies, and the remaining 13 (4.5%)

196 followed alternative study designs such as historical cohort study. Ninety-seven studies (33.4%) were

retrospective, 129 (44.5%) were prospective, 49 studies (16.9%) utilized both retrospective and

198 prospective evaluations, and the remaining studies did not specify the evaluation type utilized to assess

the intervention. Year of publication ranged from 2001 (n=2) to 2021 (n=44). Studies were most

commonly conducted in high-income countries (n=228 studies, 78.6%) with 32, 21, and 3 studies (11.0,

201 7.2, 1.0%, respectively) conducted in upper-middle, lower-middle, and low-income countries,

202 respectively. A total of 49 countries were represented across the studies that met our inclusion criteria;

USA (n=110 studies), Canada (n=16), Japan (n=15), Spain (n=15), China (n=12), and Italy (n=10) were

the most represented. Academic/teaching hospitals or tertiary care facilities were the most common

setting for intervention implementation.

Given the smaller number of studies that utilized RCTs designs and the heterogeneity across data and outcomes, a meta-analysis of RCTs was not possible; therefore, we focus our meta-analysis on interventions evaluated through pre/post observational study designs.

### 209 Theme 1: Antimicrobial use

210 Of 290 studies that described interventions in the human healthcare setting and met our eligibility criteria, we extracted AMU data, quantified as a proportion of *patients* who received an antimicrobial 211 212 before and after the study intervention, from 42 studies (Fig 2). The denominator (i.e. *patients*) was 213 defined differently in each study e.g. patients presenting at a primary healthcare facility, patients in a 214 long-term care facility. Amongst the 15 of 42 studies (35.7%) that found a statistically significant (p value 215 <0.05) pre- to post-intervention decrease in AMU; the average decrease in the proportion of patients 216 receiving various antimicrobial agents or classes was 10.4% (Standard deviation [SD]: 16.6) and the 217 range was 3.1 to 58%. Four of these studies described interventions in lower-middle-income countries 218 (Bangladesh, India, n=2, Iran), two in upper-middle-income countries (China, Malaysia), and 9 in high-219 income countries (Finland, Hong Kong, Netherlands, Spain, UK, USA, n=4). The clinical settings 220 involved in these interventions included a veteran's hospital, a university dentistry practice, a long-term 221 care facility, a pediatric hospital, primary healthcare or community clinics (n=4 studies), secondary or 222 tertiary hospitals (n=5 studies). Across these 15 studies, 7 (46.7%) assessed single interventions and the 223 remaining 8 (53.3%) tested bundled interventions; intervention duration ranged from 6 weeks to 3 years. 224 Audit or review and feedback of provider prescribing or AMU practices (n=7 studies, 46.7%) and 225 education (n=6, 40%) were the most common intervention types implemented. Four studies assessed the 226 impact of introducing various online or application-based diagnostic and clinical support tools, three studies introduced prescribing restrictions or pre-authorization requirements, two studies involved the 227 228 development and/or introduction of a clinical treatment guideline, and one study implemented a diagnostic stewardship strategy to withhold laboratory results if there were no white blood cells or 229 230 bacteria identified on microscopy.

### Fig 2. Effect of interventions on antimicrobial use (proportion of patients receiving antimicrobials).

\*Indicates significance <0.05. \*\*Indicates significance <0.001. Antimicrobial abbreviations: AMK-

amikacin, AMX- amoxicillin, AMC- amoxicillin-clavulanic acid, AMP- ampicillin, CARB- carbapenems,

234 CTX- cefotaxime, CIP- ciprofloxacin, FOF- Fosfomycin, IPM- imipenem, LVX- levofloxacin, MDR-

multi-drug resistant, MEM- meropenem, MET- methicillin, NIT- nitrofurantoin, TZP- piperacillintazobactam, SXT- trimethoprim-sulfamethoxazole, 3G-CEPH- third-generation cephalosporins. Other
abbreviations: HCAP- healthcare associated pneumonia, IV- intravenous, CAP- community-acquired
pneumonia, ICU- intensive care unit, IAI- intraabdominal infection, UTI- urinary tract infection, SSTIskin or soft tissue infection.

Six of 42 of the studies (14.3%) that reported on the proportion of patients who received an 240 antimicrobial documented a statistically significant (p value <0.05) increase in AMU after the 241 intervention; the percentage increase averaged 10.01% (SD: 14.5) and ranged from 1.1 to 58.4%. All six 242 243 of these studies described interventions in high-income countries (Denmark, Japan, Australia, USA, Spain, and Ireland); clinical settings of interventions included secondary or tertiary hospitals (n=3 244 245 studies), academic or university hospitals (n=2), and a children's hospital. The majority of these 6 studies 246 implemented bundled interventions (n=5, 83.3%); 4 included an audit or review and feedback activity; 3 247 involved the development and/or implementation of a clinical treatment guideline, protocol, or policy; 2 248 involved AMS education or training; 1 study introduced an AMS application; and another study 249 introduced a rapid blood culture diagnostic test. Intervention duration ranged from 2 months to 45 250 months.

251 Seven studies (16.7%) reported simultaneous increases and decreases in different antimicrobial 252 agents and classes that were statistically significant, ranging from a 21.3% pre- to post-intervention 253 increase to a 56% decrease. For example, Leis et al., reported a significant reduction in the proportion of patients prescribed fluoroquinolone (15.3 to 7%, p<0.001) and carbapenems (13 to 6.3%, p<0.001) and an 254 255 increase in the proportion of patients prescribed penicillin (10.9 to 32.2%, p<0.001) after an intervention that implemented a point-of-care  $\beta$ -lactam allergy skin test among other AMS activities (39). Another 256 257 intervention described by Yogo *et al.* aimed to reduce broad-spectrum antibiotic prescribing rates and treatment durations at time of hospital discharge by introducing institutional guidance for oral step-down 258 259 antibiotic selection and duration of therapy and implemented a pharmacy audit and real-time

recommendations of discharge prescriptions (40). This study documented a significant pre- to postintervention decrease in fluoroquinolone use (38.1 to 25%, p=0.001) and a significant increase in the
proportion of patients prescribed azithromycin (12 to 20%, p=0.01). Across all datapoints reported in
these 7 studies, there was an average 1.8% decrease in the proportion of patients receiving antimicrobials.

## 264 Theme 2: Appropriateness of therapy and adherence to treatment guidelines,

### 265 protocols, and policies

266 We extracted data from 38 studies that described pre- to post-intervention changes in the adherence/concordance of AMU or prescribing practices with local, national, or international treatment 267 guidelines or protocols (Fig 3). Of those, 28 studies (73.7%) reported a significant improvement in 268 269 appropriateness and/or adherence while 1 study (2.6%) reported a significant decline. Most studies that 270 reported improvements in appropriateness of therapy or adherence to guidelines were conducted in highincome countries (n=20, 71.4%, Australia; Canada, n=2; Denmark; Germany; Greece; Ireland; Israel; 271 Italy, n=3); Netherlands; USA, n=8) with 2 studies in upper-middle-income (Malaysia, South Africa), 5 in 272 273 lower-middle (Egypt; India, n=2; Kenya; Pakistan), and 1 in low-income countries (Nepal). Most studies 274 assessed bundled interventions (n=19, 67.9%) in secondary, tertiary, or academic/teaching hospital 275 settings. Audit or review and feedback; the development of implementation of clinical treatment guidelines, protocols, or policies; and education or training were the most common interventions 276 277 implemented as the sole intervention or in combination with other intervention activities in 18 (64.3%), 278 16 (57.4%), and 14 (50%) studies, respectively. Intervention duration ranged from 3 months to 6 years. The average increase in the proportion of cases or patients treated with appropriate or guideline-279 280 concordant antimicrobial therapies across all studies and indicators where a statistically significant change 281 was reported was 20.8% (SD: 12.3). The study that reported a decline in guideline concordance was 282 conducted in a secondary care hospital in the United Arab Emirates; this study assessed the impact of a 3month intervention to develop and implement a new treatment guideline and conduct educational lectures 283 284 for physicians for adopting the guidelines into their practice. The proportion of patients who received

antimicrobial treatment that complied with guidelines regarding the timing of discontinuation fell from
286 29.7 to 8.3% (Odds ratio: 0.2, 95% CI: 0.1- 0.4; Chi square p<0.001).</li>

### **Fig 3. Effect of interventions on appropriateness of antimicrobial therapy or adherence to clinical**

### 288 guidelines (including drug selection, dosage, duration, and timing of administration). \*Indicates

significance <0.05. \*\*Indicates significance <0.001.

### 290 **Theme 3: Antimicrobial stewardship**

291 We extracted AMS data from 20 studies; 9 (45%) of which demonstrated significant 292 improvements in AMS practices and 1 (5%) that reported a significant reduction in AMS practices (Fig 4). Two of three studies (66.7%) that assessed changes in intravenous to oral stepdown reported pre- to 293 post-intervention improvements in conversion rates while 7 of 18 studies (38.8%) that assessed changes 294 295 in the proportion of patients or cases where a culture or clinical diagnostic test was obtained reported significant pre- to post- increases. Of the studies the reported significant improvements in AMS, 3 were 296 297 conducted in lower-middle-income countries (Egypt, India, Vietnam), 2 in upper-middle-income countries (China, South Africa), and 4 in high-income countries (Canada; USA, n=4). Most studies 298 299 assessed bundled interventions (n=6, 66.7%) that were implemented in tertiary or academic health facilities (n=6, 66.7%). Four interventions involved the development and/or dissemination of treatment 300 301 guidelines, protocols, or policies; 4 involved education or training sessions; 4 included the introduction of 302 or changes to antibiotic order forms or clinical-support tools; 3 interventions involved audit or review and 303 feedback; 1 study included the development of a facility antibiogram. Intervention durations ranged from 304 2 months to 24 months. One study assessed the impact of a one-year audit/review and feedback 305 intervention on prescribers at a pediatric hospital in Iran obtaining blood cultures to aid in diagnosis and 306 found that the proportion of patients whose care included a blood culture for diagnosis declined from 307 23.9% pre-intervention to 4.4% post-intervention (OR: 0.1, 95% CI: 0.04-0.5; Chi square p<0.001). The study also reported non-significant pre- to post-intervention declines in the proportion of patients whose 308 309 diagnosis was aided by tracheal and urine cultures.

#### 310 Fig 4. Effect of interventions on the utilization of clinical diagnostic and laboratory tests/cultures

**and intravenous to oral conversion rates.** \*Indicates significance <0.05. \*\*Indicates significance

312 <0.001. Abbreviations: AST- antimicrobial susceptibility testing, IV- intravenous, PO- per os (by

313 mouth/oral).

314 Theme 4: Antimicrobial resistance

315 Of the studies that met our inclusion criteria and reported on our primary outcomes of interest, 11 316 reported on our secondary outcome of pre- to post-intervention changes in AMR (Fig 5). Across these 317 studies, data was reported for 60 unique organism-antimicrobial combinations. Five studies (45.5%) 318 reported significant decreases in the proportion of isolates that were resistant to antibiotics or the proportion of patients with drug-resistant infections across 17 antimicrobial-organism combinations while 319 320 3 studies (27.3%) reported both significant increases and decreases in resistance rates for different 321 antimicrobial-organism combinations. All 8 studies reporting AMR data were conducted in high-income 322 countries (Canada, Israel, France, Japan, Korea, Spain, and the USA; n=2). The 5 studies that reported 323 only decreases in resistance rates were conducted in either acute care hospitals, nursing homes, public 324 hospitals, or teaching hospitals (n=2); most of the studies tested single activity interventions (n=4, 80%)325 including introducing a treatment management protocol, and audit or review and feedback (n=3). The 326 bundled intervention consisted of the implementation of an AMS toolkit and subsequent education and an antibiotic mobile team for daily AMS coordination. 327

#### 328 Fig 5. Effect of interventions on the proportion of isolates/infections resistant to various

**329** antimicrobials. \*Indicates significance <0.05. \*\*Indicates significance <0.001. Antimicrobial

330 Abbreviations: AMK- amikacin, AMX- amoxicillin, AMC- amoxicillin-clavulanic acid, AMP-

ampicillin, CARB- carbapenems, CTX- cefotaxime, CIP- ciprofloxacin, FOF- Fosfomycin, IPM-

332 imipenem, LVX- levofloxacin, MDR- multi-drug resistant, MEM- meropenem, MET- methicillin, NIT-

- 333 nitrofurantoin, TZP- piperacillin-tazobactam, SXT- trimethoprim-sulfamethoxazole, 3G-CEPH- third-
- 334 generation cephalosporins.

335	The 3 studies that reported a combination of significant pre- to post-intervention changes were
336	conducted in nursing homes or tertiary/teaching hospitals (n=2); two of these interventions consisted of
337	bundled AMS activities. One intervention described by Ziv-On et al. consisted of review and feedback,
338	education, and restricted use of certain antibiotics that required pre-prescription authorization (41). There
339	were significant pre- to post-intervention decreases in the proportion of cultured isolates resistant to
340	gentamycin (19% to 15.4%, OR: 0.8, 95% CI: 0.677-0.888, Chi-square p<0.001) and ciprofloxacin
341	(33.8% to 29.9%, OR: 0.8, 95% CI: 0.7-0.9, Chi-square p=0.001) and significant increases in the
342	proportion of isolates resistant to cefuroxime (26.5 to 33.8%, OR: 1.4, Chi-square p<0.001) and
343	amoxicillin-clavulanic acid (29.7 to 32.6%, OR: 1.1, 95% CI: 1.03-1.3, Chi-square p=0.007). There were
344	decreases in average quarterly use of aminoglycoside (gentamycin) from 2.3 (SD: 0.2) to 1.7 (SD: 0.3)
345	daily defined doses/100 days of admission, quinolones (ciprofloxacin) 10.9 (SD: 0.7) to 6.71 (SD: 1.8),
346	second-generation cephalosporins (cefuroxime) from 11.3 (SD: 0.7) to 8.6 (SD: 2.7), and amoxicillin-
347	clavulanic acid from 19.8 (SD: 4.7) to 9.9 (SD: 3.7).
348	The second bundled study by Tandan et al. consisted of the introduction of a treatment guideline,
348 349	The second bundled study by Tandan <i>et al.</i> consisted of the introduction of a treatment guideline, education, and audit and feedback (42). There were significant decreases in the proportion of cultured <i>E</i> .
349	education, and audit and feedback (42). There were significant decreases in the proportion of cultured $E$ .
349 350	education, and audit and feedback (42). There were significant decreases in the proportion of cultured <i>E. coli</i> isolates resistant to nitrofurantoin (13.2 to 6.6%, OR: 0.5, 95% CI: 0.3-0.7. Chi-square p<0.001) and
349 350 351	education, and audit and feedback (42). There were significant decreases in the proportion of cultured <i>E. coli</i> isolates resistant to nitrofurantoin (13.2 to 6.6%, OR: 0.5, 95% CI: 0.3-0.7. Chi-square p<0.001) and trimethoprim-sulfamethoxazole (40.4 to 27.8%, OR: 0.6, 95% CI: 0.4-0.7, Chi-square p<0.001) and
349 350 351 352	education, and audit and feedback (42). There were significant decreases in the proportion of cultured <i>E. coli</i> isolates resistant to nitrofurantoin (13.2 to 6.6%, OR: 0.5, 95% CI: 0.3-0.7. Chi-square p<0.001) and trimethoprim-sulfamethoxazole (40.4 to 27.8%, OR: 0.6, 95% CI: 0.4-0.7, Chi-square p<0.001) and <i>Klebsiella pneumoniae</i> and Enterobacteriaceae to nitrofurantoin (64.4 to 47.8, OR: 0.5, 95% CI: 0.334-
349 350 351 352 353	education, and audit and feedback (42). There were significant decreases in the proportion of cultured <i>E. coli</i> isolates resistant to nitrofurantoin (13.2 to 6.6%, OR: 0.5, 95% CI: 0.3-0.7. Chi-square p<0.001) and trimethoprim-sulfamethoxazole (40.4 to 27.8%, OR: 0.6, 95% CI: 0.4-0.7, Chi-square p<0.001) and <i>Klebsiella pneumoniae</i> and Enterobacteriaceae to nitrofurantoin (64.4 to 47.8, OR: 0.5, 95% CI: 0.334-0.768; 43.9 to 38.8%, OR: 0.8, 95% CI: 0.7-1.0, respectively) but a significant increase in the proportion
349 350 351 352 353 354	education, and audit and feedback (42). There were significant decreases in the proportion of cultured <i>E.</i> <i>coli</i> isolates resistant to nitrofurantoin (13.2 to 6.6%, OR: 0.5, 95% CI: 0.3-0.7. Chi-square p<0.001) and trimethoprim-sulfamethoxazole (40.4 to 27.8%, OR: 0.6, 95% CI: 0.4-0.7, Chi-square p<0.001) and <i>Klebsiella pneumoniae</i> and Enterobacteriaceae to nitrofurantoin (64.4 to 47.8, OR: 0.5, 95% CI: 0.334- 0.768; 43.9 to 38.8%, OR: 0.8, 95% CI: 0.7-1.0, respectively) but a significant increase in the proportion of <i>Proteus</i> spp. isolates that were multi-drug resistant (6.7 to 14.8%, OR: 2.3, 95% CI: 1.1-4.6, Chi-
<ul> <li>349</li> <li>350</li> <li>351</li> <li>352</li> <li>353</li> <li>354</li> <li>355</li> </ul>	education, and audit and feedback (42). There were significant decreases in the proportion of cultured <i>E.</i> <i>coli</i> isolates resistant to nitrofurantoin (13.2 to 6.6%, OR: 0.5, 95% CI: 0.3-0.7. Chi-square p<0.001) and trimethoprim-sulfamethoxazole (40.4 to 27.8%, OR: 0.6, 95% CI: 0.4-0.7, Chi-square p<0.001) and <i>Klebsiella pneumoniae</i> and Enterobacteriaceae to nitrofurantoin (64.4 to 47.8, OR: 0.5, 95% CI: 0.334- 0.768; 43.9 to 38.8%, OR: 0.8, 95% CI: 0.7-1.0, respectively) but a significant increase in the proportion of <i>Proteus</i> spp. isolates that were multi-drug resistant (6.7 to 14.8%, OR: 2.3, 95% CI: 1.1-4.6, Chi- square p=0.02). The study did not report data on changes in AMU.
<ul> <li>349</li> <li>350</li> <li>351</li> <li>352</li> <li>353</li> <li>354</li> <li>355</li> <li>356</li> </ul>	education, and audit and feedback (42). There were significant decreases in the proportion of cultured <i>E</i> . <i>coli</i> isolates resistant to nitrofurantoin (13.2 to 6.6%, OR: 0.5, 95% CI: 0.3-0.7. Chi-square p<0.001) and trimethoprim-sulfamethoxazole (40.4 to 27.8%, OR: 0.6, 95% CI: 0.4-0.7, Chi-square p<0.001) and <i>Klebsiella pneumoniae</i> and Enterobacteriaceae to nitrofurantoin (64.4 to 47.8, OR: 0.5, 95% CI: 0.334- 0.768; 43.9 to 38.8%, OR: 0.8, 95% CI: 0.7-1.0, respectively) but a significant increase in the proportion of <i>Proteus</i> spp. isolates that were multi-drug resistant (6.7 to 14.8%, OR: 2.3, 95% CI: 1.1-4.6, Chi- square p=0.02). The study did not report data on changes in AMU. The third intervention described by Kim <i>et al.</i> tested the impact of restricting prescription of
<ul> <li>349</li> <li>350</li> <li>351</li> <li>352</li> <li>353</li> <li>354</li> <li>355</li> <li>356</li> <li>357</li> </ul>	education, and audit and feedback (42). There were significant decreases in the proportion of cultured <i>E. coli</i> isolates resistant to nitrofurantoin (13.2 to 6.6%, OR: 0.5, 95% CI: 0.3-0.7. Chi-square p<0.001) and trimethoprim-sulfamethoxazole (40.4 to 27.8%, OR: 0.6, 95% CI: 0.4-0.7, Chi-square p<0.001) and <i>Klebsiella pneumoniae</i> and Enterobacteriaceae to nitrofurantoin (64.4 to 47.8, OR: 0.5, 95% CI: 0.334-0.768; 43.9 to 38.8%, OR: 0.8, 95% CI: 0.7-1.0, respectively) but a significant increase in the proportion of <i>Proteus</i> spp. isolates that were multi-drug resistant (6.7 to 14.8%, OR: 2.3, 95% CI: 1.1-4.6, Chi-square p=0.02). The study did not report data on changes in AMU. The third intervention described by Kim <i>et al.</i> tested the impact of restricting prescription of third-generation cephalosporin through a computerized antimicrobial prescription program (43). There

but a significant increase in the proportion of extended-spectrum beta-lactamase (ESBL)-producing *K*.
 *pneumoniae* isolates (8.1% to 20.6%, OR: 2.9, 95% CI: 2.0-4.3). There was no significant change in
 carbapenem (imipenem) or beta-lactamase inhibitor use, and data on sulfonamide (trimethoprim sulfamethoxazole) use was not reported.

365

### 5 Theme 5: Clinical Outcomes

366 We extracted clinical outcome data from 57 of 301 total studies (Fig 6). Of three studies that 367 reported the proportion of patients who were admitted to the intensive care unit before and after the 368 intervention, only one reported a statistically significant change, a decrease from 44.5% to 35.5% of 369 patients (OR: 0.7, 95% CI: 0.5-1.0) (44). Three separate studies reported the proportion of patients who experienced an adverse event before and after the intervention, and one reported a statistically significant 370 371 change, an increase from 1.1% to 10.0% (OR: 9.9, 95% CI: 8.4-11.6) (45). Of 41 total studies that 372 reported data on patient mortality before and after AMS interventions, 6 (14.6%) reported statistically significant decreases in the proportion of patients who died while 2 (4.8%) reported statistically 373 374 significant increases in the proportion of patients who died; all other studies reported no significant change in mortality rates. Of 18 studies that reported on readmission rates, one study reported a 375 376 significant increase and one a significant decrease in readmission after the intervention compared to 377 before. Six of 8 studies (75%) that recorded the proportion of patients who experienced a recurrence or reinfection reported no significant pre- to post-intervention while two (25%) reported significant decreases. 378 379 Finally, three studies reported on the proportion of patients experiencing treatment failure before and after 380 interventions with only one reporting a significant pre- to post-intervention change, a decrease from 33.3% to 14.0% (OR: 0.3, 95% CI: 0.2-0.5) (46). 381

#### 382 Fig 6. Effect of interventions on clinical outcomes (ICU admission rate, adverse events, mortality,

#### 383 readmission or return visit to a health facility, recurrence of infection, and treatment failure).

\*Indicates significance <0.05. \*\*Indicates significance <0.001. Abbreviations: ICU- intensive care unit.

Based on univariable t-tests and multivariable linear regression, there were no statistically
significant (p<0.05) associations between pre- to post-intervention absolute differences and intervention</li>
type, duration, or setting of intervention across any of our study outcomes in Themes 1-5.

# 388 **Discussion**

389 Overall, there was a paucity of studies that assessed the impact of behavior-change interventions 390 on AMU, AMS, and AMR in the animal health sector; further evidence is needed to understand best 391 practices in these settings. A minority of studies conducted in the human health sector (35.7%) reported significant (p < 0.05) pre- to post-intervention decreases in AMU while a majority (73.7%) reported 392 393 significant improvements in adherence of antimicrobial therapies to local, national, or international 394 guidelines. Of 20 studies, 45% demonstrated significant improvements in AMS practices while only 1 study reported a significant reduction in AMS practices. Eleven studies reported on pre- to post-395 396 intervention changes in the AMR burden, all of which took place in high-income countries. Five of those 397 studies (45.5%) reported significant decreases in the proportion of isolates that were resistant to antibiotics or the proportion of patients with drug-resistant infections across 17 antimicrobial-organism 398 399 combinations; 3 studies (27.3%) reported both significant increases and decreases in resistance rates for 400 different antimicrobial-organism combinations. Generally, significant pre- to post-intervention changes in 401 clinical outcomes – including ICU admission, mortality, adverse events, reinfection, mortality, and 402 treatment failure rates – were infrequent with studies more commonly reporting improvements across those outcomes. Our study found no intervention characteristics that were associated with overall success 403 404 the various thematic areas in any setting or subsetting included.

This study had several limitations. We limited our review to peer-reviewed studies which may have overlooked a significant number of ongoing interventions in various settings to improve AMR, AMU, and AMS and may have also introduced a publication bias where successful studies are more likely to be more published than unsuccessful interventions. Moreover, we only considered interventions that targeted behavior change among stakeholder groups involved in the use or prescription of

410 antimicrobials thereby overlooking other important interventions such as those that aim to increase 411 awareness and knowledge of AMR, AMU, and AMS; those that effect funding levels or policies; those 412 that change access to clinically appropriate antimicrobials or other critical diagnostic and laboratory 413 testing infrastructure; among other interventions and efforts that can effectively improve AMU and AMS 414 and reduce AMR amongst human and animal populations. There were also limitations in the studies 415 included in our final analysis. First, the majority of studies took place in developed countries; given the 416 disparities in healthcare infrastructure, human resources, and AMR burden in high- versus low-resource 417 settings, our findings may not be globally applicable. Notably, adherence to guidelines was the most 418 improved intervention outcome in the human health sector; however, in many LMICs, local or national clinical treatment guidelines are often unavailable or outdated. A 2021 review of antimicrobial treatment 419 420 guidelines in Africa found that only 20 of the 55 Africa Union member states had national guidelines at 421 the time of the study, and only 10 member states had updated those guidelines since 2015 (47).

422 There were also limitations in the quality of evidence provided by the included studies. Few 423 interventions utilized random allocation of treatment groups; most interventions were assessed using 424 pre/post observational studies with no control group. The duration of interventions varied widely with 425 many only assessing short-term impacts of interventions. Moreover, few studies described the theories 426 underpinning behavior-change interventions which may improve effectiveness (48). Our quality 427 assessment examined the risk of selection bias, study design, data collection methods, intervention 428 integrity, and analyses, among other criteria. Overall, 4 of 11 studies (36.4%) that described interventions 429 in the animal health or agriculture sectors and 129 of the 290 studies (44.5%) that described interventions 430 in the human health sector were determined to have strong overall quality; therefore, there is room for 431 improvement in overall study quality.

Overall, there is a need to increase the evidence base of behavior-change interventions regarding AMU, AMS, and AMR in the animal health and LMIC settings. Due to heterogeneity in the study settings and designs, it is difficult to identify which practices are most impactful across the board. There is a need to systematize approaches to assessing the impact of interventions and for studies to collect and report

data representing the multiple ways AMR and AMS impacts clinical practice and outcomes; for example,

437 studies should consider not only overall AMU rates but the clinical appropriateness of therapy; adherence

438 to local, national, or international guidelines; clinical outcomes, AMS practices, cost and duration of

- 439 patient stays; and clinical outcomes. There is a need to systematically assess interventions to allow for a
- thorough comparative analysis so that best practices in various settings can be identified for scaling these
- 441 efforts.

# 442 Acknowledgements

- 443 We thank Nathan Freeman for assistance with the quality assessment.
- 444

# 445 **References**

446	1.	World Health Organization.	Antimicrobial resistance	[Internet].	Geneva; 2021 Nov	[cited 2022
-----	----	----------------------------	--------------------------	-------------	------------------	-------------

- 447 Sep 19]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-
- 448 resistance
- World Bank Group. Drug-Resistant Infections- A Threat to Our Economic Future. Drug-Resistant
  Infections. Washington, DC; 2017.
- 451 3. George A. Antimicrobial resistance, trade, food safety and security. One Heal [Internet]. 2018 Jun
  452 1 [cited 2022 Oct 1];5:6. Available from: /pmc/articles/PMC5725214/
- 453 4. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden
- 454 of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet [Internet]. 2022 Feb 12
- 455 [cited 2022 Sep 6];399(10325):629–55. Available from:
- 456 http://www.thelancet.com/article/S0140673621027240/fulltext
- 457 5. Nelson RE, Hatfield KM, Wolford H, Samore MH, Scott RD, Reddy SC, et al. National Estimates
- 458 of Healthcare Costs Associated With Multidrug-Resistant Bacterial Infections Among
- 459 Hospitalized Patients in the United States. Clin Infect Dis [Internet]. 2021 Jan 29 [cited 2022 Sep
- 460 6];72(Supplement\_1):S17–26. Available from:
- 461 https://academic.oup.com/cid/article/72/Supplement\_1/S17/6123350
- 462 6. Magnusson U, Moodley A, Osbjer K. Antimicrobial resistance at the livestock-human interface:
  463 implications for Veterinary Services. Rev Sci Tech Off Int Epiz. 2021;40(2).
- 464 7. Cooper B, Okello WO. An economic lens to understanding antimicrobial resistance: disruptive
- 465 cases to livestock and wastewater management in Australia. Aust J Agric Resour Econ [Internet].
- 466 2021 Oct 1 [cited 2022 Oct 1];65(4):900–17. Available from:
- 467 https://onlinelibrary.wiley.com/doi/full/10.1111/1467-8489.12450

468 8. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. C	. Global increase an
--	----------------------

- 469 geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U
- 470 S A [Internet]. 2018 Apr 10 [cited 2022 Sep 19];115(15):E3463–70. Available from:
- 471 https://www.pnas.org/doi/abs/10.1073/pnas.1717295115
- 472 9. Klein EY, Milkowska-Shibata M, Tseng KK, Sharland M, Gandra S, Pulcini C, et al. Assessment
- 473 of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of
- 474 pharmaceutical sales data. Lancet Infect Dis [Internet]. 2021 Jan 1 [cited 2022 Oct 1];21(1):107–
- 475 15. Available from: http://www.thelancet.com/article/S1473309920303327/fulltext
- 476 10. J G, M B, B W. Antibiotic prescribing practice and adherence to guidelines in primary care in the
- 477 Cape Town Metro District, South Africa. S Afr Med J [Internet]. 2018 Mar 28 [cited 2022 Oct
- 478 1];108(4):304. Available from: https://pubmed.ncbi.nlm.nih.gov/29629681/
- 479 11. Wang J, Wang P, Wang X, Zheng Y, Xiao Y. Use and prescription of antibiotics in primary health
- 480 care settings in China. JAMA Intern Med [Internet]. 2014 Dec 1 [cited 2022 Oct 1];174(12):1914–
- 481 20. Available from: https://pubmed.ncbi.nlm.nih.gov/25285394/
- 482 12. Sarwar MR, Saqib A, Iftikhar S, Sadiq T. Antimicrobial use by WHO methodology at primary
- 483 health care centers: A cross sectional study in Punjab, Pakistan 11 Medical and Health Sciences
- 484 1117 Public Health and Health Services. BMC Infect Dis [Internet]. 2018 Sep 29 [cited 2022 Oct
- 485 1];18(1):1–9. Available from: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879 486 018-3407-z
- Versporten A, Bielicki J, Drapier N, Sharland M, Goossens H, Calle GM, et al. The worldwide
  antibiotic resistance and prescribing in european children (ARPEC) point prevalence survey:
  Developing hospital-quality indicators of antibiotic prescribing for children. J Antimicrob
  Chemother. 2016;71(4):1106–17.
- 491 14. Tiseo K, Huber L, Gilbert M, Robinson TP, Van Boeckel TP. Global Trends in Antimicrobial Use

492	in Food Animals from 2017 to 2030. Antibi-	otics [Internet]. 2020 Dec 1	[cited 2022 Sep
-----	--	------------------------------	-----------------

- 493 19];9(12):1–14. Available from: /pmc/articles/PMC7766021/
- 494 15. Schar D, Klein EY, Laxminarayan R, Gilbert M, Van Boeckel TP. Global trends in antimicrobial
- 495 use in aquaculture. Sci Reports 2020 101 [Internet]. 2020 Dec 14 [cited 2022 Oct 1];10(1):1–9.
- 496 Available from: https://www.nature.com/articles/s41598-020-78849-3
- 497 16. Frost I, Craig J, Joshi J, Faure K, Laxminarayan R. Access Barriers to Antibiotics. Washington,
  498 DC; 2019.
- 499 17. Owens RC. Antimicrobial stewardship: concepts and strategies in the 21st century. Diagn
- 500 Microbiol Infect Dis [Internet]. 2008 May [cited 2022 Oct 1];61(1):110–28. Available from:
- 501 https://pubmed.ncbi.nlm.nih.gov/18384997/
- 502 18. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin

503 Microbiol Rev [Internet]. 2005 Oct [cited 2022 Oct 1];18(4):638–56. Available from:

- 504 https://pubmed.ncbi.nlm.nih.gov/16223951/
- 505 19. Garau J, Bassetti M. Role of pharmacists in antimicrobial stewardship programmes. Int J Clin
- 506 Pharm [Internet]. 2018 Oct 1 [cited 2022 Oct 1];40(5):948–52. Available from:
- 507 https://pubmed.ncbi.nlm.nih.gov/30242589/
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and
   meta-analyses: the PRISMA statement. BMJ [Internet]. 2009 Jul 21 [cited 2022 Oct
- incla-analyses. the ERISWA statement. DWJ [Include]. 2007 Jul 21 [encu 2022 Oct
- 510 10];339(7716):332–6. Available from: https://www.bmj.com/content/339/bmj.b2535
- 511 21. National Library of Medicine. Pubmed.gov [Internet]. 1996. Available from:
- 512 https://pubmed.ncbi.nlm.nih.gov/
- 513 22. Clarivate. Web of Science. 1997; Available from:
- 514 https://access.clarivate.com/login?app=wos&alternative=true&shibShireURL=https:%2F%2Fww

- 515 w.webofknowledge.com%2F%3Fauth%3DShibboleth&shibReturnURL=https:%2F%2Fwww.web
  516 ofknowledge.com%2F&roaming=true
- 517 23. Elsevier. Embase. 1947; Available from: https://www.embase.com/
- 518 24. Centre for Agriculture and Bioscience International. 1910; Available from: https://www.cabi.org/
- 519 25. Cochrane Library. Cochrane Database of Systematic Reviews. Available from:
- 520 https://www.cochranelibrary.com/cdsr/about-cdsr
- 521 26. The World Bank. World Bank Country and Lending Groups [Internet]. 2022 [cited 2022 Oct 1].
- 522 Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-
- 523 country-and-lending-groups
- 524 27. Effective Public Health Practice Project. Quality Assessment Tool for Quantitative Studies. 1998;
- 525 28. Phu DH, Cuong N Van, Truong DB, Kiet BT, Hien VB, Thu HTV, et al. Reducing Antimicrobial

526 Usage in Small-Scale Chicken Farms in Vietnam: A 3-Year Intervention Study. Front Vet Sci.

- **527** 2021 Jan 28;7:1244.
- 528 29. Hubbuch A, Peter R, Willi B, Hartnack S, Müntener C, Naegeli H, et al. Comparison of
- antimicrobial prescription patterns in calves in Switzerland before and after the launch of online
- 530 guidelines for prudent antimicrobial use. BMC Vet Res [Internet]. 2021 Dec 1 [cited 2022 Oct
- 531 1];17(1):1–14. Available from: https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-020 532 02704-w
- 533 30. Gerber M, Dürr S, Bodmer M. Reducing Antimicrobial Use by Implementing Evidence-Based,
- 534 Management-Related Prevention Strategies in Dairy Cows in Switzerland. Front Vet Sci
- 535 [Internet]. 2021 Jan 18 [cited 2022 Oct 1];7. Available from:
- 536 https://pubmed.ncbi.nlm.nih.gov/33537355/
- 537 31. Verliat F, Hemonic A, Chouet S, Le Coz P, Liber M, Jouy E, et al. An efficient cephalosporin

- 538 stewardship programme in French swine production. Vet Med Sci [Internet]. 2021 Mar 1 [cited
- 539 2022 Oct 1];7(2):432–9. Available from:
- 540 https://onlinelibrary.wiley.com/doi/full/10.1002/vms3.377
- 541 32. Collineau L, Rojo-Gimeno C, Léger A, Backhans A, Loesken S, Nielsen EO, et al. Herd-specific
- interventions to reduce antimicrobial usage in pig production without jeopardising technical and
  economic performance. Prev Vet Med. 2017 Sep 1;144:167–78.
- 544 33. Speksnijder DC, Graveland H, Eijck IAJM, Schepers RWM, Heederik DJJ, Verheij TJM, et al.
- 545 Effect of structural animal health planning on antimicrobial use and animal health variables in
- 546 conventional dairy farming in the Netherlands. J Dairy Sci [Internet]. 2017 Jun 1 [cited 2022 Oct
- 547 1];100(6):4903–13. Available from: https://pubmed.ncbi.nlm.nih.gov/28390724/
- Jensen VF, de Knegt L V., Andersen VD, Wingstrand A. Temporal relationship between decrease
  in antimicrobial prescription for Danish pigs and the "Yellow Card" legal intervention directed at
- reduction of antimicrobial use. Prev Vet Med [Internet]. 2014 Dec 1 [cited 2022 Oct 1];117(3–

4):554–64. Available from: https://pubmed.ncbi.nlm.nih.gov/25263135/


- 552 35. Singleton DA, Rayner A, Brant B, Smyth S, Noble PJM, Radford AD, et al. A randomised
- 553 controlled trial to reduce highest priority critically important antimicrobial prescription in
- 554 companion animals. Nat Commun 2021 121 [Internet]. 2021 Mar 11 [cited 2022 Oct 1];12(1):1–
- 555 14. Available from: https://www.nature.com/articles/s41467-021-21864-3
- 556 36. Lehner C, Hubbuch A, Schmitt K, Schuepbach-Regula G, Willi B, Mevissen M, et al. Effect of
- antimicrobial stewardship on antimicrobial prescriptions for selected diseases of dogs in
- 558 Switzerland. J Vet Intern Med [Internet]. 2020 Nov 1 [cited 2022 Oct 1];34(6):2418–31. Available
- from: https://pubmed.ncbi.nlm.nih.gov/33112451/
- 560 37. Hubbuch A, Schmitt K, Lehner C, Hartnack S, Schuller S, Schüpbach-Regula G, et al.
- 561 Antimicrobial prescriptions in cats in Switzerland before and after the introduction of an online


562		antimicrobial stewardship tool. BMC Vet Res [Internet]. 2020 Jul 3 [cited 2022 Oct 1];16(1):1-13.
563		Available from: https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-020-02447-8
564	38.	Hopman NEM, Portengen L, Hulscher MEJL, Heederik DJJ, Verheij TJM, Wagenaar JA, et al.
565		Implementation and evaluation of an antimicrobial stewardship programme in companion animal
566		clinics: A stepped-wedge design intervention study. PLoS One [Internet]. 2019 Nov 1 [cited 2022
567		Oct 1];14(11). Available from: https://pubmed.ncbi.nlm.nih.gov/31738811/
568	39.	Leis JA, Palmay L, Ho G, Raybardhan S, Gill S, Kan T, et al. Point-of-Care $\beta$ -Lactam Allergy
569		Skin Testing by Antimicrobial Stewardship Programs: A Pragmatic Multicenter Prospective
570		Evaluation. Clin Infect Dis [Internet]. 2017 Oct 1 [cited 2022 Nov 27];65(7):1059-65. Available
571		from: https://pubmed.ncbi.nlm.nih.gov/28575226/
572	40.	Yogo N, Shihadeh K, Young H, Calcaterra SL, Knepper BC, Burman WJ, et al. Intervention to
573		Reduce Broad-Spectrum Antibiotics and Treatment Durations Prescribed at the Time of Hospital
574		Discharge: A Novel Stewardship Approach. Infect Control Hosp Epidemiol [Internet]. 2017 May
575		1 [cited 2022 Nov 27];38(5):534–41. Available from: https://pubmed.ncbi.nlm.nih.gov/28260538/
576	41.	Ziv-On E, Friger MD, Saidel-Odes L, Borer A, Shimoni O, Nikonov A, et al. Impact of an
577		Antibiotic Stewardship Program on the Incidence of Resistant Escherichia coli: A Quasi-
578		Experimental Study. Antibiot (Basel, Switzerland) [Internet]. 2021 Feb 1 [cited 2022 Nov
579		27];10(2):1-10. Available from: https://pubmed.ncbi.nlm.nih.gov/33578840/
580	42.	Tandan M, Sloane PD, Ward K, Weber DJ, Vellinga A, Kistler CE, et al. Antimicrobial resistance
581		patterns of urine culture specimens from 27 nursing homes: Impact of a two-year antimicrobial
582		stewardship intervention. Infect Control Hosp Epidemiol [Internet]. 2019 Jul 1 [cited 2022 Nov
583		27];40(7):780–6. Available from: https://pubmed.ncbi.nlm.nih.gov/31057141/
584	43.	Kim JY, Sohn JW, Park DW, Yoon YK, Kim YM, Kim MJ. Control of extended-spectrum {beta}-

585 lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to

586		restrict third-generation cephalosporin use. J Antimicrob Chemother [Internet]. 2008 Aug [cited
587		2022 Nov 27];62(2):416–21. Available from: https://pubmed.ncbi.nlm.nih.gov/18413317/
588	44.	Shemanski S, Bennett N, Essmyer C, Kennedy K, Buchanan DM, Warnes A, et al. Centralized
589		Communication of Blood Culture Results Leveraging Antimicrobial Stewardship and Rapid
590		Diagnostics. Open Forum Infect Dis [Internet]. 2019 Sep 1 [cited 2022 Nov 27];6(9). Available
591		from: https://academic.oup.com/ofid/article/6/9/ofz321/5532664
592	45.	Shawki MA, AlSetohy WM, Ali KA, Ibrahim MR, El-Husseiny N, Sabry NA. Antimicrobial
593		stewardship solutions with a smart innovative tool. J Am Pharm Assoc (2003) [Internet]. 2021 Sep
594		1 [cited 2022 Nov 27];61(5):581-588.e1. Available from:
595		https://pubmed.ncbi.nlm.nih.gov/33962893/
596	46.	Niwa T, Yonetamari J, Hayama N, Fujibayashi A, Ito-Takeichi S, Suzuki K, et al. Clinical impact
597		of matrix-assisted laser desorption ionization-time of flight mass spectrometry combined with
598		antimicrobial stewardship interventions in patients with bloodstream infections in a Japanese
599		tertiary hospital. Int J Clin Pract [Internet]. 2019 May 1 [cited 2022 Nov 27];73(5). Available
600		from: https://pubmed.ncbi.nlm.nih.gov/30810264/
601	47.	Craig J, Hiban K, Frost I, Kapoor G, Alimi Y, Varma JK. Comparison of national antimicrobial
602		treatment guidelines, African Union. Bull World Health Organ [Internet]. 2022 Jan 1 [cited 2022
603		Apr 7];100(1):50. Available from: /pmc/articles/PMC8722630/
604	48.	Korda H, Itani Z. Harnessing social media for health promotion and behavior change. Health
605		Promot Pract [Internet]. 2013 Jan [cited 2022 Nov 29];14(1):15–23. Available from:


606 https://pubmed.ncbi.nlm.nih.gov/21558472/






						Othe Baria (068)	Confidence Internals	
					0	5	10	15
600*	BLAC (at discharge) BLAC BLAC, SXT BLAC, SXT BLAC, SXT	19.6	44.2	0.5 3.2	H+++			
swownadownownen 51-5400 60000000000000000000000000000000000	BLAC	1.6 32.4 27.5 19.6	70 16.3 44.2	4.9		•		
471	VRC BLAC (at discharge)	9.1	6.6	9.7				
70	VAN, TEC VRC	11	12.3	1.1 0.2	, <b>, , , , , , , , , , , , , , , , , , </b>			
323	VAN (C. diff)	0.3	2:4	3.8	-	•		
323	VAN (menigitis)	0.	1.2	1.8				
323	VAN (sepsis) VAN (undiagnosed) VAN (pneumonia) VAN (menigitis) VAN (IAI) VAN (C. diff) VAN (C. diff) VAN, TEC VRC VRC (c. discharge)	5:2 11.7	9.8 8.5 19.5	1.7	· · · · · ·			
605	VAN VAN (concis)	§.1	6	1.00	. It.			
523	VAN (fever, neutropenia) VAN	33.8	29.3	0.8				
523	VAN (SSTI) VAN (fever) VAN (fever, neutropenia) VAN VAN	35,8 2,6 14,3 22,1 33,8 18,6	9.8 15.8 29.3 16.7	0.5 0.6 0.7 0.8 0.9				
523	VAN (contrator inflaction)	2.6	1.2	0.1	₽I 			
190*	tZP.	.6	1.9	3.00				
298	ŤŹP (HCAP) TZP TZP VAN	40.8	§8.7	2.1	· · ·			
368	TZP	1.5	3	0.3 2.00	·			
1005*** 6004 70335 471* 2533 600* 2533 600* 2533 600* 272* 3684 70 272* 3684 702* 398* 149* 199*	SXT TGC	ó.	ů,	0.4	+			
253	SXT (at discharge)	<u>1</u> 4.1	4.8	0.6235	H			
272	SAM	1,9	1.2	0.6	·••			
471 +	POS POS QUIN SAM SAM	20.9 1.9	2.6	0.3	i+			
335	POS	0.2	0	1.00		,		
604	PEN, AMOX PMB	20	3	0.6	·•+-	_		
605**	PEN	10.9	32.2	3.9 0.6		H++		


Odds Ratio (95% Confidence Interval)





Odds Ratio (95% Confidence Interval)

			% Resi Isolates/In				
ID /	Antimicrobial				OR		
356**		Organism	Pre	Post 0		•	
	MEM	K. pneumoniae	2.5 0.2				
66 479**	CARB	All P. gomuginogg	21.2	0.02	.1 .1		
356**	TZP	P. aeruginosa		3.4		<u> </u>	
	MEM	P. aeruginosa	21.3	7.7	.3 .3 .3	Ξ.	
204**	AMX	All	52	25.7	.5		
382*	MET	S. aureus	35.5	16.1	.5	<b>⊢</b>	
66*	VAN	Enterococci spp	.4	0.2	.4 .4 .5	<b>!</b> ●	
479*	IPM	A. baumannii	13.7	6.6	.4	lei  ei	
360**	NIT	E. coli	13.2	6.6	.5	H I	
360	CARB	Proteus spp	3	1.7	.5 .5 .5		
204*	OFX	All	45	29.2	.5	10-1 10-1	
360*	NIT	K. pneumoniae	64.4	47.8	.5	1 <b>•</b> 1	
204	FOF	All	8	4.4	.6		
360**	SXT	E. coli	40.4	27.8	.6		
204*	AMP	All	78	67.3	.6	•	
360	SXT	K. pneumoniae	16.5	11.2	.6	<b>⊢●− </b>	
360	TET	K. pneumoniae	25.4	18.6	.7		
204	SXT	All	23	16.8	.6 .7 .7 .7	He H	
479**	IPM	P. aeruginosa	22.8	16.7	.7	10-1	
66	ESBL	All	0.002	0.2	.7		
360	CARB	E. coli	1	0.7	.7		
4 medRxiv preprin	nt doi: https://doi.org/10.110	01/2028071.04/372841911this version post ew) is the author/funder, who has granted is made available under a CC-BY 4.0 Inter	ted January 5, 20 medRxiv a licens	23. The copyright e to display the pr	holder for this preprint		
204	NIT	All	20	15.9	.7	H•H	
360	CIP	Proteus spp	71.9	65.7	.7	He H	
394*	MET	S. aureus	46.9	40.3	.8 .8	•	
88**	GEN	All	19	15.4	.8		
204	GEN	All	10	8	.8		
360*	NIT	Enterobacteriaceae	43.9	38.8	.8 .8 .8		
360	CIP	E. coli	56.8	52	.8		
360	LVX	Enterococci spp	60.6	55.9	.8	H•H	
88*	CIP	All	33.8	29.9	.8 .8 .9	1	
360	CIP	Enterobacteriaceae	51.7	47.7	.9	•	
88	AMP	All	71.1	68.8	.9 .9 .9	. 1	
360	TET	E. coli	41.5	39.2	.9	H	
88	SXT	All	37.8	35.6	.9	.1.	
394	LVX	E. coli	18.8	17.7	.9 .9		
360	SXT	Proteus spp	41.8	40	.9	H	
360	TET	Enterobacteriaceae	52.6	50.8	.9	. 14	
360	3G-CEPH	K. pneumoniae	18.	17	.9 .9 .9		
360	3G-CEPH	E. coli	19.7	18.8	.9	H	
360	SXT	Enterobacteriaceae	36.2	34.9	.9	H.	
360			18.1	18	1	. <b>!</b> ¶1.	
360	MDR	E. coli	15.6	15.6	1	. +++	
190	All	E. coli	100	100	1		
360	TET	Enterococcus spp	83.3	83.9	1		
360	NIT	Enterococcus spp	13.8	14.4	1		
360	AMP	Enterococcus spp	17.6	18.4	1.1		
382	MET	S. aureus	14.6	15.3	1.1		
190	All	P. aeruginosa	87.4	88.3	1.1	H <b>P</b> -1	
360	3G-CEPH	Proteus spp	8.3	9.3	1.1	H <b>-</b>	
88*	AMC	All	29.7	32.6	1.1	•	
394	LVX	E. coli	30.4	33.9	1.2	₩●⊣	



Odds Ratio (95% Confidence Interval)



Odds Ratio (95% Confidence Interval)